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Abstract 17 
Bifidobacterial carbohydrate metabolism has been studied in considerable detail for a variety 18 
of both plant and human-derived glycans, particularly involving the bifidobacterial prototype 19 
Bifidobacterium breve UCC2003. We recently elucidated the metabolic pathways by which 20 
the human milk oligosaccharide (HMO) constituents lacto-N-tetraose (LNT), lacto-N-21 
neotetraose (LNnT) and lacto-N-biose (LNB) are utilized by B. breve UCC2003. However, to 22 
date no work has been carried out on the regulatory mechanisms that control expression of 23 
the genetic loci involved in these HMO metabolic pathways. In the current study, we describe 24 
the characterization of three transcriptional regulators and corresponding operator and 25 
associated (inducible) promoter sequences, the latter governing transcription of the genetic 26 
elements involved in LN(n)T/LNB metabolism. The activity of these regulators is dependent 27 
on the release of specific monosaccharides, which are believed to act as allosteric effectors, 28 
and which are derived from the corresponding HMOs targeted by the particular locus.  29 
 30 
Importance 31 
Human milk oligosaccharides (HMOs) are a key factor in the development of the breastfed 32 
infant microbiota. They function as prebiotics, selecting for a specific range of microbes, 33 
including a number of infant-associated species of bifidobacteria, which are thought to 34 
provide a range of health benefits to the infant host. While much research has been carried 35 
out on elucidating the mechanisms of HMO metabolism in infant-associated bifidobacteria, 36 
there is to date very little understanding of the transcriptional regulation of these pathways. 37 
The current study reveals a multi-component transcriptional regulation system that controls 38 
the recently-identified pathways of HMO metabolism in the infant-associated 39 
Bifidobacterium breve prototype strain UCC2003. This not only provides insight into the 40 
regulatory mechanisms present in other infant-associated bifidobacteria, but also provides an 41 
example of a network of sequential steps regulating microbial carbohydrate metabolism.  42 
  43 
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Introduction 44 
Bifidobacteria represent high-G+C, Gram-positive, anaerobic members of the phylum 45 
Actinobacteria, and are common commensals of the mammalian, avian and insect gut. In 46 
humans, they are particularly abundant and prevalent among the gut microbiota of healthy, 47 
vaginally-delivered, breastfed infants (2), and are thought to confer a multitude of benefits to 48 
the neonatal host (3-5). For this reason, as well as because of their purported health-49 
promoting activities in adults, bifidobacteria are used as functional ingredients in a variety of 50 
foods and therapeutic products. The use of prebiotics is also becoming commonplace for the 51 
improvement of both adult and infant (gut) health. A prebiotic has been defined as ‘a non-52 
digestible food ingredient that beneficially affects the host by selectively stimulating the 53 
growth and/or activity of one or a limited number of bacteria in the colon, and thus improves 54 
host health’ (6).  55 
Fascinatingly, the archetypal prebiotic would appear to be human breastmilk, and in 56 
particular its bifidogenic constituents known as Human Milk Oligosaccharides (HMOs). 57 
HMOs represent specific glycans present in human breastmilk that are thought to shape, at 58 
least partly, the compositional structure of the neonatal gut microbiota (7, 8). HMOs 59 
represent, after lactose, the second-largest carbohydrate component of breastmilk (7, 9), and 60 
constitute a heterogeneous mix of at least 200 distinct glycan structures (10). The majority of 61 
complex HMO structures can be classified into one of two types, depending on their 62 
backbone composition. The more abundant Type I HMOs contain the core tetrasaccharide 63 
lacto-N-tetraose (LNT) within their structure (Galβ1-3GlcNAcβ1-3Galβ1-4Glc). Type II 64 
HMOs contain lacto-N-neotetraose (LNnT), a stereoisomer of LNT, within their backbone 65 
(Galβ1-4GlcNAcβ1-3Galβ1-4Glc). Lacto-N-biose (LNB; Galβ1-3GlcNAc) is a subunit of 66 
LNT and other Type I HMO structures, and can be released by the degradation of these 67 
sugars (11).   68 
The effects of the specific human breastmilk components on the prevalence, abundance and 69 
activity of members of the infant gut microbiota are currently enjoying a great deal of 70 
scientific and commercial attention, due to the beneficial roles they are believed to play in 71 
infant health and development (12, 13). Understanding the pathways by which specific 72 
HMOs are metabolized by particular microbial species that inhabit the infant gut is important, 73 
although our knowledge regarding these processes is still in its infancy, particularly with 74 
regards to the manner in which they affect microbiota development.  75 
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It is hardly surprising that the dominant Bifidobacterium species found among the neonatal 76 
gut microbiota can utilise various HMO components as their sole carbohydrate source (10). 77 
These species chiefly include strains of Bifidobacterium bifidum, Bifidobacterium longum 78 
subsp. infantis and Bifidobacterium breve. HMO utilization by B. bifidum and B. longum 79 
subsp. infantis is relatively well characterised. B. bifidum extracellularly hydrolyses complex 80 
HMO structures, including LNT and LNnT, employing secreted glycosyl hydrolases, 81 
followed by the internalisation and intracellular degradation/metabolism of (most of) the 82 
resulting mono- and di-saccharides, such as LNB (11, 14-20). B. longum subsp. infantis 83 
internalises intact LNT, LNnT and LNB, and uses a series of sequential 84 
hydrolytic/phosphorolytic reactions acting from the non-reducing end of the carbohydrate 85 
structures to degrade them into their monosaccharide components for further metabolic 86 
processing (10, 11, 21-24). However, B. infantis has also been demonstrated to take up and 87 
utilise fucosyl- and sialyl-lactose (25-27). 88 
The metabolic pathways of LNT, LNnT and LNB have recently been elucidated in the 89 
prototype strain B. breve UCC2003 (28). In the latter study, converging pathways of LNT 90 
and LNnT catabolism were identified, where monosaccharide moieties are sequentially 91 
released from the non-reducing end of either sugar by hydrolytic reactions. The genetic units 92 
responsible for the uptake and breakdown of these structures are the lnt locus (corresponding 93 
to locus tags Bbr_0526-0530) and the nah locus (locus tags Bbr_1554-1560) (Table 3 and 94 
Fig. 1). The lnt locus encodes proteins that are responsible for the internalisation of LNT and 95 
intracellular hydrolysis of both LNT and LNnT, releasing a galactose (Gal) moiety from their 96 
non-reducing end, and at the same time liberating the trisaccharide lacto-N-triose 97 
(GlcNAcβ1-3Galβ1-4Glc). The nah locus specifies an LNT/LNnT uptake system, while it 98 
furthermore encodes a glycosyl hydrolase which liberates GlcNAc from the non-reducing end 99 
of lacto-N-triose, leaving lactose, which itself is further degraded by lactose-specific glycosyl 100 
hydrolases. Additionally, the gene products of the lnp/glt locus (corresponding to locus tags 101 
Bbr_1585-1590; Table 3 and Fig. 1) are responsible for the internalisation and subsequent 102 
phosphorolysis of free LNB, releasing its constituent monosaccharides Gal-6-phosphate and 103 
GlcNAc (28, 29). We also identified the transcriptional upregulation of genes in the nag locus 104 
(locus tags Bbr_1247-1252; Table 3 and Fig. 1) during growth on LNT, LNnT and LNB, 105 
indicating their role in the utilisation of these sugars, specifically in the multi-step 106 
metabolism of GlcNAc. The nag locus has previously been implicated in the metabolism of 107 
sialic acid and mucin-derived N-glycans, both of which contain GlcNAc as well (30, 31). 108 
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While the degradation routes of these key HMO structures have thus been identified, the 109 
regulatory mechanisms that control expression of these pathways have remained unexplored, 110 
both for B. breve and HMO-utilising Bifidobacterium species as a whole. 111 
In the current study, we identified and characterized the genes encoding transcriptional 112 
regulators responsible for control of gene expression in four key HMO-associated loci in B. 113 
breve UCC2003 during growth on LNT, LNnT or LNB.  114 
 115 
Results 116 
Identification of putative transcriptional regulator-encoding genes in the vicinity of 117 
HMO-utilisation loci. In a previous study, we had observed that genes within four 118 
chromosomal loci exhibit transcriptional induction during growth of B. breve UCC2003 on 119 
LNT, LNnT or LNB as the sole carbohydrate source (28). This indicates that these genes are 120 
subject to transcriptional regulation, which was presumed to be either directly or indirectly 121 
controlled by the presence of these HMO substrates. The four loci concerned are: the lnt 122 
locus (Bbr_0526-530), the nah locus (Bbr_1554-1560), the nag locus (Bbr_1247-1250) and 123 
the lnp/glt locus (Bbr_1585-1590) (Fig. 1; see Table 3 for a description of [predicted] 124 
functions). Detailed scrutiny of these four loci and neighbouring regions showed that the lnt 125 
and nah loci are flanked by or contain a predicted regulator-encoding gene, respectively: lntR 126 
(Bbr_0526), encoding a LacI-type repressor, and nahR (Bbr_1555), encoding a NagC/XylR-127 
type repressor (Fig. 1A and 1B). The nag locus is associated with two genes, nagR1 128 
(Bbr_1249) and nagR2 (Bbr_1251), both predicted to encode ROK/NagC family-type 129 
repressors, while no regulator-encoding gene was observed in close vicinity of the lnp/glt 130 
locus (Fig. 1C and 1D). NagC/XylR-type and ROK/NagC-type repressors are both members 131 
of the large family of ROK-type transcriptional regulators (32). The four identified putative 132 
regulator-encoding genes were thus selected as candidates for mutagenesis in order to 133 
ascertain their role, if any, in the transcriptional regulation of the lnt, nah, nag and lnp/glt 134 
loci.  135 
 136 
Generation and transcriptomic analysis of insertional mutants in putative HMO-137 
associated regulator-encoding genes. Individual insertional mutants were constructed in 138 
lntR, nahR, nagR1 and nagR2, resulting in B. breve strains UCC2003-lntR, UCC2003-nahR, 139 
UCC2003-nagR1 and UCC2003-nagR2, respectively (see Materials and Methods). In order 140 
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to identify promoters/genes that are subject to transcriptional control of these predicted 141 
regulators, global gene transcription data was obtained from microarray-based analyses 142 
performed on the B. breve UCC2003-lntR, UCC2003-nahR, UCC2003-nagR1 and 143 
UCC2003-nagR2 insertion mutants, grown in mMRS supplemented with ribose, as compared 144 
to the transcriptome of the UCC2003 wild type strain grown under the same conditions. 145 
Transcriptome analysis of the lntR mutant revealed the upregulation of the adjacent lntP1, 146 
lntP2, lntA and lntS genes of the lnt locus (Table 3 and Fig. 1), when this mutant was grown 147 
on ribose (as compared to wild type UCC2003), all of which were also previously found to be 148 
upregulated in expression during growth of wild type UCC2003 on LNT or LNnT (28). This 149 
corroborates the notion that LntR is a LacI-type repressor and that this protein negatively 150 
regulates the LNT/LNnT-dependent transcription of genes within the lnt cluster. Conversely, 151 
the array data obtained for the nahR mutant only revealed transcriptional upregulation 152 
(compared to the UCC2003 control) of the nahS gene (Table 3), when grown on ribose. This 153 
is consistent with previously observed expression patterns in UCC2003, with the exception of 154 
nahA, which may have been expected to exhibit transcriptional upregulation in the nahR 155 
mutant, as its expression was increased during growth on LNT and LNnT in B. breve 156 
UCC2003 (28). These results suggest that NahR, a NagC/XylR-type repressor, is responsible 157 
for the transcriptional regulation of at least one gene of the nah cluster. For the nagR1 158 
mutant, upregulation of nagA2, nagB3 and nagK (but not nagR2 or nagK2), as well as all of 159 
the genes of the lnp/glt locus (Table 3) was observed when grown on ribose (as compared to 160 
the UCC2003 control). These results suggest that NagR1, a ROK/NagC family-type 161 
repressor, is responsible for the transcriptional regulation of (part of) the nag and lnb clusters. 162 
This is consistent with transcriptomic data previously obtained for wild type UCC2003 163 
during growth on LN(n)T and LNB, which demonstrated the transcriptional upregulation of 164 
genes in both of these loci (28). When the transcriptome of UCC2003-nagR2 was compared 165 
to that of UCC2003 when grown on ribose, the nagR2 mutant exhibited increased 166 
transcription of genes in the mal locus (locus tags Bbr_0118-0123), which is known to be 167 
involved in maltooligosaccharide metabolism (33, 34), and Bbr_1719-1721 (predicted to 168 
function in fatty acid metabolism) (35) (data not shown), none of which are predicted to 169 
function in HMO metabolism, nor were shown to be upregulated in our previous wild type 170 
arrays on LNT, LNnT or LNB (28). These results thus show that NagR2 is not involved in 171 
the transcriptional control of the loci responsible for LNT, LNnT or LNB metabolism, and no 172 
further investigation of this regulator was carried out. The lntR, nahR and nagR1 genes, 173 
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however, were selected for further study, as described below, in order to further elucidate 174 
their regulatory activity and specificity.  175 
 176 
Promoter mapping through identification of the transcription start sites. Based on the 177 
transcriptome findings, we presumed that LntR, NahR and NagR1 act as transcriptional 178 
regulators of (certain genes of the) lnt, nah and nag/lnp/glt loci, respectively. Gene 179 
expression patterns observed for the regulator gene mutants, and examination of the genetic 180 
layout and transcriptome profiles of these loci allowed us to assign putative promoter-181 
containing regions within each locus. In order to verify these predicted promoter regions, the 182 
associated transcription start sites (TSS) were experimentally determined by primer extension 183 
analyses.  184 
The lnt locus was deduced to contain at least two promoters: one just upstream of lntP1 (Fig. 185 
2A) and one in front of lntS (Fig. 2B). The lntP1 and lntS genes on the B. breve UCC2003 186 
genome encode a permease and a solute-binding protein of an ABC-transporter system, 187 
respectively, and exhibit an increase in transcription upon growth on LNT, LNnT, LNB, 188 
lactosamine or lactose (28). The transcription start sites (TSS) of the presumed lntP1 and lntS 189 
promoters were determined by primer extension analysis using RNA extracted from B. breve 190 
UCC2003 grown in mMRS supplemented with 1 % LNnT. An extension product was 191 
identified 41 nucleotides 5’ of the predicted translational start site of the lntP1 gene 192 
(Supplemental Fig. S1A), while the TSS for the lntS gene was identified 154 nucleotides 5’ 193 
of the predicted translational start site (Supplemental Fig. S1B). In both cases, the TSS was 194 
preceded by -10 and -35 hexamers that resemble (bifidobacterial) consensus vegetative 195 
promoter recognition sequences (36, 37).   196 
The nah locus was deduced to contain at least two promoters: one just upstream of nahS (Fig. 197 
2C) and one in front of nahA (Fig. 2D). The nahS and nahA genes on the B. breve UCC2003 198 
genome encode a solute-binding protein of an ABC-transporter system, and a GH20 N-199 
acetylhexosaminidase, respectively. While an increase in transcription was only observed for 200 
nahS in the nahR mutant-based array, both this gene and nahA were found to be subject to 201 
transcriptional induction when wild-type UCC2003 is grown on LNT, LNnT or lactosamine 202 
(28). The TSSs of the presumed nahS and nahA promoters were determined by primer 203 
extension analysis using RNA extracted from B. breve UCC2003 grown in mMRS 204 
supplemented with 1 % LNnT. An extension product was identified 59 nucleotides 5’ of the 205 
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predicted translational start site for the nahS gene (Supplemental Fig. S1C), while the TSS 206 
upstream of nahA was identified 74 nucleotides 5’ of the predicted nahA translational start 207 
site (Supplemental Fig. S1D). The nahS upstream region contained a -10 and a -35 hexamer 208 
just upstream of the TSS resembling bifidobacterial promoter sequences (36, 37), while in the 209 
case of the nahA promoter region the TSS is preceded by a sequence that resembles a 210 
canonical -10 promoter sequence, although no associated -35 hexamer could be identified. 211 
The nag and lnp/glt loci were each deduced to contain at least two promoters, just upstream 212 
of the genes: nagB3 (Fig. 2E) and nagK (Fig. 2F), and lnpB (Fig. 2G) and gltA (Fig. 2H), 213 
respectively, based on the associated genetic lay-out coupled to transcription patters of the 214 
nagR1 mutant or when UCC2003 was grown on LNB (28). The transcription start sites (TSS) 215 
of the presumed nagB3, nagK, lnpB and gltA promoters were determined by primer extension 216 
analysis using RNA extracted from B. breve UCC2003 grown in mMRS supplemented with 1 217 
% LNB. An extension product was identified 155 nucleotides 5’ of the predicted translational 218 
start site for the nagB3 gene (Supplemental Fig. S1E), while the transcriptional start site of 219 
nagK was identified 35 nucleotides 5’ of the predicted translational start site (Supplemental 220 
Fig. S1F). An extension product was identified 43 nucleotides 5’ of the predicted 221 
translational start site for the lnpB gene (Supplemental Fig. S1G), while the transcription start 222 
site for the gltA gene was identified 44 nucleotides 5’ of the predicted translational start site 223 
(Supplemental Fig. S1H). All four regions contained -10 and -35 hexamers just upstream of 224 
the TSS that resembled bifidobacterial vegetative promoter recognition sequences. 225 
 226 
Identification of regulator-operator interactions using electromobility shift assays and 227 
in silico analysis. In order to establish if the LntR, NahR and NagR1 proteins directly and 228 
specifically interact with operator sequences within the identified promoter regions of the lnt, 229 
nah, and nag/lnp/glt gene clusters, respectively, electrophoretic mobility shift assays 230 
(EMSAs) were performed. For the purpose of performing EMSAs, the lntR, nahR and nagR1 231 
genes were first individually cloned into the nisin-inducible vector pNZ8150 with an N-232 
terminal His tag-encoding sequence to facilitate protein expression and purification in L. 233 
lactis NZ9000 (see Materials and Methods). As had been noted previously for other 234 
regulators from bifidobacteria (38-40), LntR, NahR and NagR1 could be obtained as purified 235 
proteins, but had lost their DNA binding activity during some stage of the purification 236 
process. Thus, instead of purified protein, crude cell extracts of (nisin-induced) L. lactis 237 
NZ9000 pNZ-lntRHis, L. lactis NZ9000 pNZ-nahRHis and L. lactis NZ9000 pNZ-nagR1His 238 
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were used to carry out the EMSAs. Crude cell extract obtained from nisin-induced L. lactis 239 
NZ9000 pNZ8150 (empty vector) incubated with the respective DNA fragments was used as 240 
a negative control. The DNA fragments used were various short amplicons representing 241 
different segments of the putative promoter regions (Fig. 2, Supplemental Table S1). 242 
LntR-containing crude extract was shown to specifically bind to the IRD700-labelled DNA 243 
fragments lntP1a and lntP1b, but not with lntP1c (Fig. 2A, Supplemental Table S1). A double 244 
mobility-shift was observed for fragment lntP1a, indicative of two distinct LntR binding sites 245 
being present on this fragment, while a single mobility shift was visible for fragment lntP1b. 246 
Similarly, LntR was able to bind to IRD700-labelled DNA fragments lntSb and lntSa, in the 247 
latter case being visible as a double mobility-shift (suggesting the presence of two distinct 248 
LntR-binding sites), while no binding was observed with lntSc (Fig. 2B, Supplemental Table 249 
S1). Inspection and comparison of the four fragments in which binding was observed 250 
revealed the presence of at least one complete conserved sequence, representing an inverted 251 
repeat, in all four fragments, while two such conserved sequences were observed in 252 
fragments lntP1a and lntSa (being consistent with the observed double mobility-shift). 253 
Comparative analysis of these inverted repeats identified a 14-nucleotide consensus sequence 254 
(Fig. 3A), containing a conserved ‘CG’ at its centre, which is a well-documented conserved 255 
feature of operator sequences bound by LacI-type regulators (41, 42). This consensus 256 
sequence furthermore contains a conserved 5’ ‘TG’ and 3’ ‘CA’ at its flanking ends, a feature 257 
previously documented in operator sequences identified for other LacI-type regulators 258 
encoded by B. breve UCC2003 (39, 43, 44). In both promoter regions, one such presumed 259 
operator sequence was found closely downstream of or partially overlapping the predicted -260 
10 element of the promoter region, while the second was found closely upstream of the 261 
predicted -35 element of the promoter region (Supplemental Fig. S1A, S1B). The positions of 262 
these identified operators are consistent with LntR acting as a repressor for the identified lnt 263 
promoters (45, 46). 264 
The results obtained with the L. lactis NZ9000 pNZ-nahRHis crude extract demonstrated 265 
specific binding to the IRD700-labelled DNA fragments nahSa and nahSb, but not with 266 
nahSc (Fig. 2C, Supplemental Table S1). Furthermore, binding was observed for IRD700-267 
labelled DNA fragment nahAa, but not to fragment nahAb or nahAc (Fig. 2D, Supplemental 268 
Table S1). Sequence inspection and comparison of the NahR-bound DNA fragments revealed 269 
the presence of an inverted repeat sequence, which was common to these fragments, yet not 270 
present in fragments to which NahR did not bind. These inverted repeat elements therefore 271 
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represent putative operator sequences required for the NahR protein. Further analysis of these 272 
inverted repeats identified a 10-nucleotide consensus sequence (Fig. 3B). Conserved 5’ C and 273 
3’ G nucleotides at the extreme flanks of this consensus sequence have previously been 274 
observed for operator sequences of certain NagC/XylR-type regulators (47). The presumed 275 
operator upstream of nahS overlaps with the downstream end of the predicted -10 promoter 276 
element (Supplemental Fig. S1C), while the nahA-associated operator was found to be 277 
roughly 110 bp upstream of the predicted -10 element (Supplemental Fig. S1D). The position 278 
of the identified nahS operator, and the consensus obtained between this and the putative 279 
operator identified for nahA, confirm the function of NahR as a repressor for nahS. While 280 
binding of NahR may occur at the nahA operator, its binding does not appear to directly 281 
interfere with the nahA promoter. This agrees with the lack of upregulation in nahA 282 
expression observed for the nahR mutant, though the transcriptional role of NahR in this case, 283 
if any, is not clear. The mapped locations of the operator, -10 and -35 sequences are shown in 284 
Supplemental Figure S1.  285 
The results obtained with the crude extract obtained from nisin-induced L. lactis NZ900 pNZ-286 
nagR1His revealed specific binding to the IRD700-labelled DNA fragments nagB3a, nagB3b 287 
and nagB3c (with a weak apparent double-shift observed for nagB3a), but not to fragment 288 
nagB3d (Fig. 2E, Supplemental Table S1). Specific binding was identified for IRD700-289 
labelled DNA fragment nagKa, while no binding was detected when fragment nagKb was 290 
used (Fig. 2F, Supplemental Table S1). Binding of the NagR protein was also demonstrated 291 
for the IRD700-labelled DNA fragments lnpBa and lnpBc, but not with lnpBb (Fig. 2G, 292 
Supplemental Table S1). Finally, NagR1 was shown to bind IRD700-labelled DNA 293 
fragments gltAa, gltAb and gltAc (Fig. 2H, Supplemental Table S1). Inspection and 294 
comparison of the nagB3, nagK, lnpB, and gltA-associated fragments in which binding was 295 
observed revealed the presence of a common sequence, representing an inverted repeat (with 296 
two repeats present in the fragment nagB3a, consistent with the observed double-shift), while 297 
being absent within fragments for which no binding was observed. These sequence motifs are 298 
presumed to act as operator sequences for the NagR1 protein. In silico analysis of these 299 
inverted repeat sequences revealed a 23-nucleotide consensus (Fig. 3C). Interestingly, while 300 
this obtained consensus motif bears little resemblance to many previously proposed binding 301 
motifs for ROK/NagC family-type repressors from other bacteria (48), a substantial degree of 302 
similarity can be observed to motifs identified previously for other ROK/NagC-type 303 
regulators encoded by B. breve UCC2003 (31, 39). The putative nagB3, nagK, lnpB and gltA 304 
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operators were all found to be overlapping with or encompassing the predicted -10 or -35 305 
elements (Supplemental Fig. S1E, S1F, S1G, S1H). The positions of these identified 306 
operators corroborate the notion that NagR1 acts as a transcriptional repressor of its target 307 
genes (i.e. nagB3, nagK, lnpB and gltA).  308 
 309 
Identification of transcriptional effectors. In order to identify effectors that control the 310 
binding activity of LntR, NahR and NagR1, we performed EMSAs with fragments containing 311 
the binding motifs for each regulator, in the presence of a range of carbohydrates, including: 312 
lactose, LNB, LNT, LNnT, galactose, galactose-6-phosphate (Gal-6-P), galactose-1-313 
phosphate (Gal-1-P), GlcNAc, GalNAc or glucose (at a standard concentration of 20 mM) 314 
(Supplemental Fig. S2). These carbohydrates were chosen as they include both the complete 315 
structures and various components of LNT, LNnT or LNB. Carbohydrates which did not 316 
elicit any effect on fragment binding by the regulator (at a concentration of 20 mM) were 317 
assumed not to represent transcriptional effectors for that particular regulator. If an inhibition 318 
in binding was observed at 20 mM, the EMSA was repeated at a range of descending 319 
concentrations (or in some cases higher concentrations were used for a related molecule [e.g. 320 
Gal, Gal-1-P and Gal-6-P]). For LntR, galactose was found to reduce binding of this regulator 321 
to its DNA targets at a concentration of 10 mM or less (Fig. 4A). Gal-6-P and Gal-1-P were 322 
also found to reduce target DNA binding of LntR, but at considerably higher, and perhaps 323 
biologically irrelevant concentrations of ≥20 mM (Supplemental Figure S3). For NahR, only 324 
GlcNAc was found to reduce interaction between NahR and its DNA target at a minimum 325 
concentration of 0.0625 mM (Fig. 4B), while in the case of NagR1, Gal-6-P was found to 326 
prevent NagR1-binding activity at a minimum concentration of 1 mM (Fig. 4C, 4D). 327 
 328 
Discussion 329 
The dominance of (certain) bifidobacteria within the breastfed neonatal gut microbiota (2) is 330 
substantially aided by the ability of these infant-associated species to utilise indigestible 331 
HMO residues as a carbon source (10). Our previous work demonstrated that consumption 332 
and utilisation of LNT, LNnT or LNB by B. breve UCC2003 is facilitated by interrelated 333 
catabolic pathways (28). While pathways for HMO utilisation in other Bifidobacterium 334 
species have been identified and elucidated (14, 22, 23), very little work has been carried out 335 
with regard to their regulation. Our results reveal molecular details of the transcriptional 336 
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regulation of B. breve UCC2003 loci responsible for LN(n)T/LNB metabolism, and provide 337 
insights into how metabolism of these HMOs is controlled in B. breve UCC2003.  338 
In the current study, we identified four transcriptional regulators, three of which were shown 339 
to be involved in regulating LN(n)T/LNB metabolism in UCC2003. Microarray analysis of 340 
insertional mutants in lntR, nahR, nagR1 and nagR2 identified genes under the regulation of 341 
each encoded regulator. LntR and NahR were shown to represent ‘local’ regulators, i.e. 342 
controlling transcription of genes adjacent to lntR and nahR, respectively. In contrast, NagR1 343 
regulates transcription of not only the ‘local’ nag locus, but also of the genetically unlinked 344 
lnp/glt locus. We also investigated the transcriptome effect of a mutation in Bbr_1251 345 
(nagR2), however, the affected genes are not believed to be involved in HMO metabolism, 346 
but apparently in malto-oligosaccharide and fatty acid metabolism. While LacI-type, 347 
NagC/XylR-type and ROK/NagC-type regulators have all previously been identified and 348 
characterised in B. breve UCC2003 (31, 38, 39, 43), functional analysis of regulators in other 349 
bifidobacteria is comparatively undocumented. However, a recent study identified 350 
homologous transcription factors for those of LntR, NagR1and NagR2 in a range of different 351 
Bifidobacterium species (49). 352 
Details of promoter and operator sequences specific to the LntR, NahR and NagR1 regulators 353 
were elucidated using a combination of electromobility shift and primer extension analyses. 354 
These operator results, for the most part, agree with those predicted by Khoroshkin et al. (49). 355 
The operator sequences predicted in their study concur with our experimentally determined 356 
data, both in approximate location and number, for both LntR and NagR1, with the exception 357 
of one additional predicted operator for LntR, and two for NagR1. An additional NagR1 358 
operator sequence was predicted upstream of gltA, however, this did not appear to be 359 
functional, based on the lack of a double mobility-shift in the EMSA’s for that region. This 360 
operator may indeed be a non-functional relic resulting from a duplication event. Khoroshkin 361 
et al. (49) also predicted an operator sequence upstream of the gene Bbr_1884 for NagR1 362 
binding, though we did not examine this. However, based on the predicted functions of this 363 
gene in the Bifid Shunt, it may also be tied into the overall regulation of LNB and LacNAc 364 
metabolism carried out by NagR1. An additional LntR operator was predicted upstream of 365 
lntR itself, which may function in lntR transcriptional auto-regulation. The observed lack of 366 
upregulation in nahA transcription for the nahR mutant appears discordant with the 367 
transcriptional increase of this gene that was previously observed in wild type UCC2003 368 
during growth on LN(n)T (28), as well as the presence of the functional nahA operator 369 
 o
n
 M
arch 9, 2018 by UNIV CO
LLEG
E CO
RK
http://aem
.asm
.org/
D
ow
nloaded from
 
13 
 
sequence for NahR binding identified in this study. However, this may be explained if 370 
transcriptional induction of nahA is mediated by both LntR and NahR. This possibility is 371 
corroborated by the presence of an inverted repeat sequence resembling an LntR operator and 372 
this intriguing possibility merits further experimental investigation.  373 
Perhaps most interestingly of all was the identification of the effectors for each 374 
transcriptional regulator. Binding of LntR to its targets is impeded by Gal, NahR-mediated 375 
operator binding is prevented by the presence of GlcNAc, while NagR1-operator interaction 376 
is prevented by the presence of Gal-6-P. In each case, the genes under transcriptional control 377 
by their respective regulator encode the metabolic machinery responsible for the release of 378 
the effector monosaccharide from the substrate at that metabolic step. For example, Gal is 379 
released from the non-reducing end of LN(n)T through the hydrolytic activity of LntA, which 380 
is encoded by the lnt locus (28). Transcriptional repression of this locus is thus believed to be 381 
relieved by the presence of the released monosaccharide, which is presumed to interact with 382 
the allosteric effector site typical of LacI-type repressors (39, 45, 50, 51). A similar scenario 383 
applies to GlcNAc release which acts as the effector for the NahR regulator that controls 384 
transcription of nahS, and to Gal-6-P which governs the activity of the NagR1, the presumed 385 
transcriptional regulator of the lnp/glt and nag loci. The possible dual regulation of nahA 386 
transcription, as mentioned above, would mean that both the presence of the lnt locus activity 387 
product (and LntR effector) galactose, and the nah locus activity product (and NahR effector) 388 
GlcNAc, are required for the induction of nahA expression. This provides an extra level of 389 
transcriptional and thus metabolic control, ensuring the expression of nahA strictly during 390 
LN(n)T metabolism, despite GlcNAc release during metabolism of other sugars, such as 391 
LNB, sialic acid and sulphated GlcNAc (28, 30, 31). Interestingly, in the case of Gal-6-P and 392 
NagR1, the lnp/glt locus is required for the degradation of LNB, though the nag locus is not 393 
directly involved in this, yet plays a role in N-acetylglucosamine (GlcNAc) and sialic acid 394 
metabolism (30). This may not be surprising, as sialic acid residues are commonly found in 395 
HMO (7), and more importantly, GlcNAc is a breakdown product of LNB (as well as LNT 396 
and LNnT).  397 
Interestingly, previous work has shown that transcriptional induction takes place of the lnt 398 
locus during growth of UCC2003 on galacto-oligosaccharides (GOS) (52). This would appear 399 
to disagree with the high degree of specificity of transcriptional induction by effectors of 400 
these HMO-associated loci. However, it is worth noting that GOS consist mainly of galactose 401 
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(53, 54), and that the intracellular release of galactose during GOS metabolism by UCC2003 402 
would be sufficient to cause transcriptional induction of the lnt locus. 403 
Thus, the presence and initial degradation of such a structure (i.e. LNT, LNnT or LNB) 404 
indirectly induces further expression of the locus required for its degradation, until the sugar 405 
is no longer available, at which point the absence of inducers will cause a return to 406 
transcriptional repression. Initial internalisation and degradation is likely facilitated by a low 407 
level of ‘leaky’ gene expression of the locus. In the case of LNT and LNnT degradation, this 408 
regulation is a two-step process, at the level of LN(n)T degradation first (by the lnt locus), 409 
and then at the level of (LN(n)T breakdown product) lacto-N-triose degradation (by the nah 410 
locus). Regulation of LNB metabolism is managed in a single step, at the level of LNB 411 
phosphorolysis (by the lnp/glt locus). We see that all three regulators in this transcriptional 412 
control network belong to distinct families of regulator proteins, despite functioning in 413 
similar roles as saccharide-controlled repressors. In conclusion, our results reveal a tightly 414 
controlled system for transcriptional regulation of genes encoding the metabolic machinery 415 
required for (certain) HMO metabolism in B. breve UCC2003. Such tight regulation is 416 
necessary for infant-associated bifidobacteria such as B. breve, where switching metabolic 417 
processing to and from milk-derived sugars such as HMO and lactose, and plant-derived 418 
carbohydrate sources (55) is a regular occurrence during the weaning period. Moreover, this 419 
suggests the evolution of specific catabolic responses to the presence of and for the utilisation 420 
of specific HMO moieties by B. breve, and poses the question as to whether such regulatory 421 
systems have similarly evolved in other infant-associated Bifidobacterium species. 422 
 423 
Materials and Methods 424 
Bacterial strains, plasmids, and culture conditions. Bacterial strains and plasmids used in 425 
this study are listed in Table 1. B. breve UCC2003 was routinely cultured in either de Man 426 
Rogosa and Sharpe medium (MRS medium; Difco, BD, Le Pont de Claix, France) 427 
supplemented with 0.05 % cysteine-HCl or reinforced clostridial medium (RCM; Oxoid Ltd., 428 
Basingstoke, England). Growth of bifidobacterial strains for transcriptional and primer 429 
extension analyses was carried out in modified de Man Rogosa and Sharpe (mMRS) medium, 430 
which was prepared from first principles (56), and which does not contain a fixed 431 
carbohydrate source. Prior to inoculation, the mMRS medium was supplemented with 432 
cysteine-HCl (0.05 %, wt/vol) and a particular carbohydrate source (1 %, wt/vol). It has 433 
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previously been shown that mMRS does not support growth of B. breve UCC2003 in the 434 
absence of an added carbohydrate (57). Carbohydrates used were ribose (Sigma Aldrich, 435 
Steinheim, Germany), LNB (Elicityl Oligotech, Crolles, France) and LNnT (Glycom, 436 
Lyngby, Denmark). A 1 % wt/vol concentration of carbohydrate was considered sufficient to 437 
encourage adequate growth for RNA harvesting. The addition of these carbohydrates did not 438 
significantly alter the pH of the medium, and therefore subsequent pH adjustment was not 439 
required. 440 
B. breve cultures were incubated under anaerobic conditions in a modular atmosphere-441 
controlled system (Davidson and Hardy, Belfast, Ireland) at 37°C. Lactococcus lactis strains 442 
were cultivated in M17 broth (Oxoid Ltd., Basingstoke, England) containing 0.5 % glucose 443 
(58) at 30°C. Escherichia coli strains were cultured in Luria-Bertani (LB) broth (59) at 37°C 444 
with agitation. Where appropriate, growth media contained tetracycline (Tet; 10 μg ml-1), 445 
chloramphenicol (Cm; 5 μg ml-1 for L. lactis and E. coli, 2.5 μg ml-1 for B. breve), 446 
erythromycin (Em; 100 μg ml-1) or kanamycin (Kan; 50 μg ml-1). Recombinant E. coli EC101 447 
cells containing (derivatives of) pORI19 were selected on LB agar containing Em and Kan, 448 
and supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (40 μg 449 
ml
-1
) and 1 mM IPTG (isopropyl-β-D-galactopyranoside).  450 
 451 
Nucleotide sequence analysis. Sequence information was obtained from the Artemis-452 
mediated (60) genome annotations of B. breve UCC2003 (61). Database searches were 453 
performed using non-redundant sequences accessible at the National Center for 454 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov) using the basic local 455 
alignment search tool (BLAST) (62, 63). Sequences were verified and analysed using the 456 
SeqMan and SeqBuilder programs of the DNAStar software package (version 10.1.2; 457 
DNAStar, Madison, WI, USA). 458 
 459 
DNA Manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as 460 
previously described (64). Plasmid DNA was isolated from Escherichia coli, Lactococcus 461 
lactis and B. breve using the Roche High Pure Plasmid Isolation kit (Roche Diagnostics, 462 
Basel, Switzerland). An initial lysis step was performed using 30 mg ml
-1
 of lysozyme for 30 463 
minutes at 37°C prior to plasmid isolation from L. lactis or B. breve. Procedures for DNA 464 
manipulations were essentially performed as described previously (59). All restriction 465 
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enzymes and T4 DNA ligase were used according to the supplier’s instructions (Roche 466 
Diagnostics, Basel, Switzerland). Synthetic single stranded oligonucleotide primers used in 467 
this study (Table 2) were synthesized by Eurofins (Ebersberg, Germany). Standard PCRs 468 
were performed using Taq PCRmaster mix (Qiagen) or Extensor Hi-Fidelity PCR Master 469 
Mix (Thermo Scientific, Waltham, United States) in a Biometra T3000 thermocycler 470 
Biometra, Göttingen, Germany) or a Life Technologies Proflex PCR System (Thermo 471 
Scientific, Waltham, United States). PCR products were visualized by ethidium bromide 472 
(EtBr) staining following agarose gel electrophoresis (1 % agarose). B. breve colony PCR 473 
reactions were performed as described previously (65). PCR fragments were purified using 474 
the Roche high Pure PCR purification kit (Roche Diagnostics, Basel, Switzerland). Plasmid 475 
DNA was isolated using the Roche High Pure Plasmid Isolation kit (Roche Diagnostics, 476 
Basel, Switzerland). Plasmid DNA was introduced into E. coli by electroporation as 477 
described previously (59). B. breve UCC2003 (66) and L. lactis (67) were transformed by 478 
electroporation according to published protocols. Correct orientation of DNA inserts and 479 
integrity of all plasmid constructs (see also below) were verified by DNA sequencing, 480 
performed at Eurofins (Ebersberg, Germany). 481 
 482 
Construction of B. breve UCC2003 insertion mutants. Internal fragments of Bbr_0526 483 
(designated here as lntR) (367 base pairs [bp] representing codon numbers 40 through to 162 484 
of the 320 codons of this gene), Bbr_1249 (designated here as nagR1) (502 bp representing 485 
codon numbers 64 through to 231 of the 375 codons of this gene), Bbr_1251 (designated here 486 
as nagR2) (507 bp representing codon numbers 62 through to 230 of the 405 codons of this 487 
gene), and Bbr_1555 (designated here as nahR) (448 bp representing codon numbers 74 488 
through to 223 of the 380 codons of this gene) were amplified by PCR using B. breve 489 
UCC2003 chromosomal DNA as a template and primer pairs 526LacIInsFHindIII and 490 
526LacIInsRXbaI, 1249LacIInsFHindIII and 1249LacIInsRXbaI, 1251LacIInsFHindIII and 491 
1251LacIInsRXbaI, or 1555LacIInsFHindIII and 1555LacIInsRXbaI (Table 2), respectively. 492 
The insertion mutants were constructed using a previously described approach (65), 493 
generating mutant strains B. breve UCC2003-lntR, B. breve UCC2003-nagR1, B. breve 494 
UCC2003-nagR2 and B. breve UCC2003-nahR, which carried disrupted lntR, nagR1, nagR2 495 
and nahR genes, respectively (Table 1). Site-specific recombination of potential tet-resistant 496 
mutant isolates was confirmed by colony PCR using primer combinations TetWF and TetWR 497 
to verify tetW gene integration, and primers Bbr_526ConfirmP1 or Bbr_526ConfirmP2, 498 
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Bbr_1249ConfirmP1 or Bbr_1249ConfirmP2, Bbr_1251ConfirmP1 or Bbr_1251ConfirmP2, 499 
and Bbr_1555ConfirmP1 or Bbr_1555ConfirmP2 (positioned upstream of the selected 500 
internal fragments of Bbr_0526, Bbr_1249, Bbr_1251 and Bbr_1555, respectively) in 501 
combination with primer TetWF to confirm integration at the correct chromosomal location 502 
(Table 2).  503 
 504 
Analysis of global gene expression using B. breve DNA microarrays. Global gene 505 
expression was determined during log-phase growth of the insertional mutant strains B. breve 506 
UCC2003-lntR, B. breve UCC2003-nagR1, B. breve UCC2003-nagR2 and B. breve 507 
UCC2003-nahR in mMRS supplemented with ribose. The generated transcriptome data sets 508 
were compared to the transcriptome information obtained for log-phase wild-type B. breve 509 
UCC2003 cells when grown in mMRS supplemented with ribose. Ribose was selected as a 510 
suitable transcriptomic reference, as the metabolic pathway and gene expression profile for 511 
growth of UCC2003 on ribose is known and has been employed previously as a reference 512 
(44, 68). DNA microarrays containing oligonucleotide primers representing each of the 1864 513 
identified open reading frames on the genome of B. breve UCC2003 were designed and 514 
obtained from Agilent Technologies (Palo Alto, Ca., USA). Methods for cell disruption, 515 
RNA isolation, RNA quality control, complementary DNA synthesis and labelling were 516 
performed as, described previously (69). Two independent biological replicates were used for 517 
each array using a Cy3/Cy5 dye-swap, as described previously (69). Labelled cDNA was 518 
hybridized using the Agilent Gene Expression hybridization kit (part number 5188-5242) as 519 
described in the Agilent Two-Colour Microarray-Based Gene Expression Analysis v4.0 520 
manual (publication number G4140-90050). Following hybridization, microarrays were 521 
washed in accordance with Agilent’s standard procedures and scanned using an Agilent DNA 522 
microarray scanner (model G2565A). Generated scans were converted to data files with 523 
Agilent's Feature Extraction software (Version 9.5). DNA-microarray data were processed as 524 
previously described (70-72). Differential expression tests were performed with the Cyber-T 525 
implementation of a variant of the t-test (73).  526 
 527 
Construction of overexpression vectors, protein overproduction and purification. For 528 
the construction of plasmids pNZ-lntR, pNZ-nagR1 and pNZ-nahR, DNA fragments 529 
encompassing lntR, nagR1 and nahR were generated by PCR amplification from 530 
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chromosomal DNA of B. breve UCC2003 using Q5 High-Fidelity DNA polymerase and 531 
primer combinations 526PurFSmaI and 526PurRXbaI, 1249PurFPvuII and 1249PurRXbaI, 532 
or 1555PurFEcoRV and 1555PurXbaI, respectively (Table 2). An in-frame N-terminal His10-533 
encoding sequence was incorporated into the forward primers 526PurFSmaI, 1249PurFPvuII 534 
and 1555PurFEcoRV to facilitate downstream protein purification. The generated amplicons 535 
were digested with SmaI and XbaI, PvuII and XbaI, or EcoRV and XbaI, respectively, and 536 
ligated into the ScaI and XbaI digested, nisin-inducible translational fusion plasmid pNZ8150 537 
(74). The ligation mixtures were introduced into L. lactis NZ9000 by electrotransformation 538 
and transformants were then selected based on chloramphenicol (Cm) resistance. The plasmid 539 
content of a number of Cm-resistant transformants was screened by restriction analysis and 540 
the integrity of positively identified clones was verified by sequencing. 541 
Nisin-inducible gene expression and protein overproduction was performed as described 542 
previously (38, 43, 75). In brief, 50 ml of M17 broth supplemented with 0.5 % (wt/vol) 543 
glucose was inoculated with a 2 % inoculum of a particular L. lactis strain, followed by 544 
incubation at 30°C until an OD600 of 0.5 was reached, at which point protein expression was 545 
induced by addition of cell-free supernatant of a nisin-producing strain (76), followed by 546 
continued incubation for a further 2 hours. Cells were harvested by centrifugation, and crude 547 
cell extract was obtained as described previously (39). Although protein purification of LntR-548 
His, NahR-His and NagR1-His was achieved using His tag affinity chromatography, the 549 
purification procedure appeared to render the proteins inactive in subsequent electrophoretic 550 
mobility shift assays (EMSAs). For this reason, crude cell extracts, prepared in a 10 mM Tris-551 
HCl lysis buffer (pH 7.0), were adopted for the EMSAs (see below). 552 
 553 
Electrophoretic mobility shift assay (EMSA). DNA fragments representing different 554 
portions of the promoter regions upstream of lntP1 (locus tag Bbr_0527) and lntS (locus tag 555 
Bbr_0530), nagB3 (locus tag Bbr_1248) and nagK (locus tag Bbr_1250), lnpB (locus tag 556 
Bbr_1586) and gltA (locus tag Bbr_1590) and nahS (Bbr_1554) and nahA (Bbr_1556) were 557 
prepared by PCR using IRD700-labelled primers pairs (Integrated DNA Technologies, 558 
Coralville, Indiana, United States) (Table 2). EMSAs were performed essentially as described 559 
previously (43, 77). In all cases, binding reactions were carried out in a final volume of 20 µl 560 
in the presence of poly[d(I-C)] in binding buffer (20 mM Tris-HCl, 5 mM MgCl2, 0.5 mM 561 
DTT, 1 mM EDTA, 100 mM KCl, 10 % glycerol). Varying amounts of crude protein extract, 562 
ranging from 140 ng to 180 ng, of the LntR-, NahR-, or NagR1-(over)producing L. lactis 563 
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NZ9000 strain constructed, and a fixed amount of DNA probe (0.1 pmol) was mixed on ice 564 
and subsequently incubated for 15 min at 37°C. In order to assess if the binding activity of 565 
LntR, NahR, or NagR1 is modulated by a carbohydrate ligand, various carbohydrates 566 
including galactose, galactose-1-phosphate, galactose-6-phosphate (all Sigma Aldrich, 567 
Steinheim, Germany), LNT (Glycom, Lyngby, Denmark), LNnT (Glycom, Lyngby, 568 
Denmark), LNB (Elicityl Oligotech, Crolles, France), glucose, N-acetylglucosamine, N-569 
acetylglucosamine-6-phosphate or lactose (all Sigma Aldrich, Steinheim, Germany) ranging 570 
in concentration from 50 to 0.0625 mM, were included to the binding reaction buffer. 571 
Samples were loaded onto a 6 % non-denaturing PAA gel prepared in TAE buffer (40 mM 572 
Tris acetate [pH 8.0], 2 mM EDTA) and run in a 0.5-to-2.0 x gradient of TAE at 100 V for 90 573 
min in an Atto Mini PAGE system (Atto Bioscience and Biotechnology, Tokyo, Japan). 574 
Signals were detected using Odyssey Infrared Imaging System (Li-Cor Biosciences UK Ltd, 575 
Cambridge, UK) and captured using the supplied software Odyssey V3.0. 576 
Primer extension analysis. Total RNA was isolated from B. breve UCC2003, grown in 577 
mMRS supplemented with 1 % LNnT or 1 % LNB, to early exponential phase, using a 578 
previously described Macaloid method (78). RNA samples were treated with RNase-free 579 
DNase (Ambion). Primer extension was performed by annealing 1 pmol of IRD700 synthetic 580 
18-mer oligonucleotides to 15 μg of RNA as described previously (79). Sequence ladders of 581 
the presumed promoter regions immediately upstream of lntP1, lntS, nagB3, nagK, lnpB, 582 
gltA, nahS or nahA, amplified from both UCC2003 genomic DNA which were run alongside 583 
the primer extension products, were produced using the same primer as the primer extension 584 
reaction and employing the Thermo Sequenase Primer Cycle Sequencing Kit; Amersham. 585 
Separation was achieved on a 6.5 % Li-Cor Matrix KB Plus acrylamide gel. Signal detection 586 
and image capture was performed by means of a Li-Cor sequencing instrument (Li-Cor 587 
Biosciences). 588 
 589 
Operator Consensus Sequence Prediction, using MEME and WEBLOGO online 590 
software tools. Co-regulated promoter regions were assessed for the presence of operator 591 
sequences by the use of the MEME (Multiple Em for Motif Elicitation) online tool 592 
(http://meme-suite.org/tools/meme) (80), which were the visualized by the WebLogo online 593 
tool (http://weblogo.berkeley.edu/logo.cgi) (81, 82). Sequences used for consensus sequence 594 
prediction are given in Supplemental Table S2. 595 
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 596 
Microarray data accession number. The microarray data obtained in this study have been 597 
deposited in NCBI’s Gene Expression Omnibus database and are accessible through GEO 598 
Series accession number GSE105108. 599 
 600 
 601 
 602 
 603 
 604 
 605 
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Figure 1. Schematic representation of HMO metabolism-associated loci in B. breve 848 
UCC2003, as identified preciously [22]. (a) The genes of the lnt locus. (b) The genes of the 849 
nah locus. (c) The genes of the nag locus, and adjacent genes nagR2 and nagK2. (d) The 850 
genes of the lnp/glt locus. The length of the arrows is proportional to the size of the open 851 
reading. Genes shown in red possess a predicted promoter in their upstream intergenic region. 852 
Genes shown in green are predicted to encode a regulator protein. Genes shown in blue were 853 
identified as not possessing a predicted promoter in their upstream intergenic region. 854 
 855 
Figure 2. EMSA images showing (a) LntR, (b) NahR, and (c) and (d) NagR1 interactions 856 
with a range of DNA fragments from the regions in the proximity of their predicted target 857 
promoters, in order to identify their approximate locations.  The locations and sizes of 858 
fragments used, in relation to the promoter regions’ respective transcription start sites, are 859 
given in Supplemental Table S1. The panels below schematically represent the locations of 860 
the DNA fragments used in relation to the locations of the putative operator sequences (red 861 
boxes), transcription start sites (green arrow) and genes (blue box arrows). In each panel, ‘-’ 862 
indicates a negative control, where an equivalent amount crude cell extract from NZ9000 863 
harbouring empty pNZ8150 was added instead of crude extract from the regulator-expressing 864 
NZ9000 strain.  865 
 866 
Figure 3. WebLogo representation of the operator motif consensus sequences for (a) the 867 
LacI-type regulator LntR, (b) the NahC/XylR-typr regulator NahR and (c) the ROK/NagC-868 
type regulator NagR1, predicted using in silico analysis. Predicted operator sequences 869 
identified in the intergenic regions containing the co-regulated promoters for each regulator 870 
using the MEME online tool. Motif consensuses were generated by inputting these predicted 871 
operator sequences to the WebLogo online tool. The locations and sequences of each operator 872 
are shown alongside their respective consensus sequence.   873 
 874 
Figure 4. EMSA images showing (a) LntR, (b) NahR, and (c) and (d) NagR1 interactions 875 
with promoter-containing DNA fragments, with the addition of a gradient of their respective 876 
inducers, ranging from 0mM-20mM. In each panel, ‘C’ indicates a negative control, where an 877 
equivalent amount crude cell extract from NZ9000 harbouring empty pNZ8150 was added 878 
instead of crude extract from the regulator-expressing NZ9000 strain.  879 
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 880 
Figure 5. Schematic representation of the proposed model for transcriptomic regulation of 881 
LNT, LNnT and LNB metabolism by B. breve UCC2003. LNT and LNnT are internalised 882 
and intracellularly degraded through sequential hydrolysis and release of monosaccharides 883 
from their non-reducing ends. These released monosaccharides act as effectors relieving 884 
transcriptional repression of the loci encoding the cellular components responsible for 885 
liberation of these glycans. As such, liberated galactose relieves transcriptional repression of 886 
the lnt locus, and N-acetylglucosamine relieves transcriptional repression of the nah locus. 887 
Similarly, intracellular degradation of LNB (derived from the extracellular hydrolysis of 888 
complex HMO structures by other infant GIT microbes) releases N-acetylglucosamine and 889 
galactose-6-phosphate, the latter of which relieves transcriptional repression of the lnp/glt and 890 
nag loci. 891 
 892 
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Table 1: Bacterial plasmids and strains used in this work. 
Cmr, Emr,Kmr and Tetr, resistance to chloramphenicol, erythromycin, kanamycin and tetracycline, respectively. 
UCC, University College Cork Culture Collection. 
Strain or plasmid Relevant Features Reference or 
Source 
Strains   
Escherichia coli strains   
 E. coli EC101 Cloning host, repA+ km+ (43) 
 E. coli EC101-pNZ-M.BbrII + M.BbrIII EC101 harbouring pNZ8048 derivative containing bbrIIM and bbrIIIM (41) 
Lactococcus lactis strains   
 L. lactis NZ9000 MG1363, pepN::nisRK, nisin-inducible overexpression host (55) 
 L. lactis NZ9700 Nisin-producing strain (55) 
 L. lactis NZ9000-pNZ-lntR NZ9000 conatining pNZ-lntR This study 
 L. lactis NZ9000-pNZ-nahR NZ9000 conatining pNZ-nahR This study 
 L. lactis NZ9000-pNZ-nagR1 NZ9000 conatining pNZ-nagR1 This study 
Bifidobacterium sp. Strains   
 B. breve UCC2003 Isolate from nursling stool (42) 
 B. breve UCC2003-lntR pORI19-tet-bbr_0526 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nahR pORI19-tet-bbr_1555 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nagR1 pORI19-tet-bbr_1249 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nagR2 pORI19-tet-bbr_1251 insertion mutant of UCC2003 This study 
 
Plasmids 
  
 pAM5 pBC1-puC19-Tetr (1) 
 pORI19 Emr, repA-, ori+, cloning vector (43) 
 pORI19-tet-lntR Internal 367 bp fragment of bbr_0526 and tetW cloned in pORI19 This study 
 pORI19-tet-nahR Internal 448 bp fragment of bbr_1554 and tetW cloned in pORI19 This study 
 pORI19-tet-nagR1 Internal 502 bp fragment of bbr_1249 and tetW cloned in pORI19 This study 
 pORI19-tet-nagR2 Internal 507 bp fragment of bbr_1251 and tetW cloned in pORI19 This study 
 pNZ8150 Cmr, nisin inducible translational fusion vector (51) 
 pNZ-lntR Cmr, pNZ8150 derivative containing translational fusion of Bbr_0526 encoding 
DNA fragment to nisin inducible promoter 
This study 
 pNZ-nahR Cmr, pNZ8150 derivative containing translational fusion of Bbr_1555 encoding 
DNA fragment to nisin inducible promoter 
This study 
 pNZ-nagR1 Cmr, pNZ8150 derivative containing translational fusion of Bbr_1249 encoding 
DNA fragment to nisin inducible promoter 
This study 
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Table 2: Oligonucleotide primers used in this work. 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold, and His-tag sequences 
incorporated into nucleotide primer sequences are indicated in italics. 
 
 
Purpose Primer Sequence (5’-3’) 
Cloning of Bbr_0526 in pNZ8150 526F 
526R 
 
tgcatccccgggatgcatcaccatcaccatcaccatcaccatcacgcgagaccaacacaggtttcc 
tgcgcatctagacgtttcccgtataccattaatcag 
 
Cloning of Bbr_1555 in pNZ8150 1555F 
1555R 
 
tgcatcgatatcatgcatcaccatcaccatcaccatcaccatcactacgctaaatccaatccc 
tgcgcatctagacggcggcacggtgatctg 
Cloning of Bbr_1249 in pNZ8150 1249F 
1249R 
 
tgcatccagctgatgcatcaccatcaccatcaccatcaccatcactcgtatcccggtcttgcc 
tgcatccagctgatgtcgtatcccggtcttgcc 
 
Cloning of internal 465bp fragment of 
Bbr_0526 in pORI19 
IM526F 
IM526R 
 
ctggtcaagcttcgttgaagccgcgatgga 
ctggtctctagagtcaacggtggggcagtg 
 
Cloning of internal 488bp fragment of 
Bbr_1555 in pORI19 
IM1555F 
IM1555R 
 
ctggtcaagcttgctggccatcgatacggac 
ctggtctctagactcgtcgttcagcagcac 
Cloning of internal 443bp fragment of 
Bbr_1249 in pORI19 
IM1249F 
IM1249R 
 
ctggtcaagcttcgaagaaggcctattgcg 
ctggtctctagacagcagaatcgccgaacc 
 
Cloning of internal 488bp fragment of 
Bbr_1251 in pORI19 
IM1251F 
IM1251R 
 
ctggtcaagcttgaagagaccggcgacctgg 
ctggtctctagagccattgtcgatgacgcc 
 
Amplification of tetW tetWFw 
tetWRv 
 
tcagctgtcgacatgctcatgtacggtaaggaagca 
gcgacggtcgaccataacttctgattgttgccg 
 
Confirmation of site specific homologous 
recombination 
526confirm1 
526confirm2 
1555confirm1 
1555confirm2 
1249confrim1 
1249confrim2 
1251confrim1 
1251confrim2 
 
gcgctagctgttacaatggtc 
gccatttccaacccctctc 
tacgctaaatccaatccc 
gacgcaagggccaacaaccgc 
catacagccgccacggcac 
tcgtatcccggtcttgcc 
gcagacgatactgcacgcg 
gtcaagcatctctaccac 
Amplification of Bbr_0527 promoter fragments 
with IRD700-labelled oligonucleotides 
527IRDfa 
527IRDra 
527IRDfb 
527IRDrb 
527IRDfc 
527IRDrc 
 
ctcgcccctcgcttgtctctc 
gcataggcacggcagcgac 
attgttttcgtgaccattg 
gaataatgaacacgaacacg 
caattttggtcaaccttcg 
cgcgcgtagttctcgac 
Amplification of Bbr_0530 promoter fragments 
with IRD700-labelled oligonucleotides 
530IRDfa 
530IRDra 
530IRDfb 
530IRDrb 
530IRDfc 
530IRDrc 
 
gccgaacggtgtgctggtgg 
cttcatcgttctgttctccttc 
cgataacacgcccgccatc 
gctggacttgccgctatc 
cttcatagagccacttc 
ctcgaagtccttggcaac 
Amplification of Bbr_1554 promoter fragments 
with IRD700-labelled oligonucleotides 
1554IRDfa 
1554IRDra 
1554IRDfb 
1554IRDrb 
1554IRDfc 
1554IRDrc 
 
gtcgctgggattggatttagcg 
gtggctatgactgcgcgc 
cggctttcaggataacaccca 
ggatttggcggcgcgatc 
ccaaacaaaatagttgctacggc 
gttgagtgcggtgtaggtctcc 
Amplification of Bbr_1556 promoter fragments 
with IRD700-labelled oligonucleotides 
 
 
 
 
1556IRDfa 
1556IRDra 
1556IRDfb 
1556IRDrb 
1556IRDfc 
1556IRDrc 
 
ctggacggctgctcaaagc 
gcagagatgtttgaccgttcat 
ggtgacgacgccactctgc 
gtggtttgcggttgccct 
gccatctcaggaccgaacg 
ggtcgtcaaggtgatgaatcc 
Amplification of Bbr_1248 promoter fragments 
with IRD700-labelled oligonucleotides 
 
 
 
 
1248IRDfa 
1248IRDra 
1248IRDfb 
1248IRDrb 
1248IRDfc 
1248IRDrc 
1248IRDfd 
1248IRDrd 
 
cctcctgcctgaacgatg 
gacaatgatgatttccggc 
gttagggaacttcactaatacattcc 
cctgggagatgtcgatcgactc 
gtccgtacgtccataattgtaagtag 
cctgggagatgtcgatcgactc 
gatgggcggctttgggcag 
cctgggagatgtcgatcgactc 
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 Table 2: Oligonucleotide primers used in this work. 
Purpose Primer Sequence (5’-3’) 
Amplification of Bbr_1250 promoter fragments with IRD700-
labelled oligonucleotides 
1250IRDfa 
1250IRDra 
1250IRDfb 
1250IRDrb 
 
gatgccgttgtggtagagatg 
ggtgttatcagtcattgcctatcc 
gcgtgtcgcgtatgaggc 
ggtgttatcagtcattgcctatcc 
Amplification of Bbr_1586 promoter fragments with IRD700-
labelled oligonucleotides 
1586IRDfa 
1586IRDra 
1586IRDfb 
1586IRDrb 
1586IRDfc 
1586IRDrc 
 
cggttcgtcgaaaatccaag 
cagtgcgaagtgtgaggcg 
gccgcttattgcggctttatag 
ctttgagggcagaagtaactagttc 
gtatgcgcgttcgtccac 
ctttgagggcagaagtaactagttc 
Amplification of Bbr_1590 promoter fragments with IRD700-
labelled oligonucleotides 
 
1590IRDfa 
1590IRDra 
1590IRDfb 
1590IRDrb 
1590IRDfc 
1590IRDrc 
 
ggcccgctggcagattag 
ggcaagagcagccacgatg 
gacagatgtctgagcggtc 
gaatcgggcagacggtgc 
cgcgcagaaattgttagttagg 
gaatcgggcagacggtgc 
Amplification of region containing Bbr_0527 promoter region 
for sequencing ladders 
527promF 
527promR 
 
gcattgctgtcattcgccacac 
gaataatgaacacgaacacg 
Amplification of region containing Bbr_0530 promoter region 
for sequencing ladders 
530promF 
530promR 
 
gcgtgcggatgaaactgg 
gtctggaacggcttggcgc  
Amplification of region containing Bbr_1554 promoter region 
for sequencing ladders 
1554promF 
1554promR 
 
cgtttcctcgaccccagttc 
gaatgtgtccttgagcttggc 
Amplification of region containing Bbr_1556 promoter region 
for sequencing ladders 
1556promF 
1556promR 
 
ctggacggctgctcaaagc 
ggtcgtcaaggtgatgaatcc 
Amplification of region containing Bbr_1248 promoter region 
for sequencing ladders 
1248promF 
1248promR 
 
ggaggctttggcggtacgg 
cctgggagatgtcgatcgactc 
Amplification of region containing Bbr_1250 promoter region 
for sequencing ladders 
1250promF 
1250promR 
 
gatgccgttgtggtagagatg 
ggtgccacccacatcaacac 
Amplification of region containing Bbr_1586 promoter region 
for sequencing ladders 
1586promF 
1586promR 
 
gcgagaccttcgaccttcagcc 
cggcacgagattgtaagacac 
Amplification of region containing Bbr_1590 promoter region 
for sequencing ladders 
1590promF 
1590promR 
 
ggcccgctggcagattag 
gaatcgggcagacggtgc 
527 promoter for primer extension analysis 527PE 
 
gcataggcacggcagcgac 
530 promoter for primer extension analysis 530PE 
 
cttcatcgttctgttctccttc 
1554 promoter for primer extension analysis 1554PE 
 
gttcatgttggtcttctttcc 
1556 promoter for primer extension analysis 1556PE 
 
gcagagatgtttgaccgttcat 
1248 promoter for primer extension analysis 1248PE 
 
ctgcccaaagccgcccatc 
1250 promoter for primer extension analysis 1250PE 
 
ggtgttatcagtcattgcctatcc 
1586 promoter for primer extension analysis 1586PE 
 
gcgatgtcaaatagtgtttcc 
1590 promoter for primer extension analysis 1590PE ggcaagagcagccacgatg 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold, and His-tag sequences 
incorporated into nucleotide primer sequences are indicated in italics. 
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1 
 
Table 3. B. breve UCC2003 regulator mutant genes upregulated in transcription during 1 
growth in mMRS medium supplemented with 1 % ribose as the sole carbohydrate, as 2 
compared to the wild type (control).  3 
The level of transcription is shown as a fold-value of increase in transcription on each carbohydrate, as compared to a ribose control, with a 4 
cut-off of a minimum 2.0-fold increase in transcription.  5 
a Based on comparative transcriptome analysis using B. breve UCC2003-lntR, B. breve UCC2003-nahR and B. breve UCC2003-nagR1 6 
grown on 1% ribose, as compared to wild-type B. breve UCC2003 grown under the same conditions as a control. Two independent 7 
biological replicates were used for each array using a Cy3/Cy5 dye-swap. 8 
b The cutoff point is 2.0-fold, with a P value of _0.001. —, value below the cutoff. 9 
N/A indicates that the fold-value for increase in transcription for this gene is not included, as this is the gene in which the mutation was 10 
made, and thus does not accurately represent its natural transcription under these conditions.  11 
The level of transcription is not given for the regulator-encoding genes containing the mutations in their respective arrays, as their 12 
transcription has been interrupted, and thus cannot be considered as reliable.  13 
    Fold upregulationa,b during growth on: 
Gene ID Gene name Function UCC2003-
lntR 
UCC2003-
nahR 
UCC2003-
nagR1 
Bbr_0526 lntR Transcriptional regulator, LacI family N/A - - 
Bbr_0527 lntP1 Permease protein of ABC transporter system for sugars  3.84 - - 
Bbr_0528 lntP2 Permease protein of ABC transporter system for sugars  3.77 - - 
Bbr_0529 lntA GH42 Beta-galactosidase 2.78 - - 
Bbr_0530 
 
lntS Solute-binding protein of ABC transporter system for sugars  5.66 - - 
Bbr_1247 nagA2 CE9 nagA2 N-acetylglucosamine-6-phosphate deacetylase - - 6.70 
Bbr_1248 nagB3 nagB3 Glucosamine-6-phosphate isomerase  - - 9.11 
Bbr_1249 nagR1 Transcriptional regulator, ROK family  - - N/A 
Bbr_1250 
 
nagK Sugar kinase, ROK family  - - 2.29 
Bbr_1251 nagR2 Transcriptional regulator, ROK family  - - - 
Bbr_1252 
 
nagK2 Sugar kinase, pfkB family  - - - 
Bbr_1554 nahS Solute-binding protein of ABC transporter system (lactose)  - 17.44 - 
Bbr_1555 nahR NagC/XylR-type transciptional regulator - N/A - 
Bbr_1556 nahA GH20 nagZ Beta-N-acetylhexosaminidase - - - 
Bbr_1558 nahP Permease protein of ABC transporter system - - - 
Bbr_1559 nahT1 ATP-binding protein of ABC transporter system - - - 
Bbr_1560 
 
nahT2 ATP-binding protein of ABC transporter system - - - 
Bbr_1585 lnpD UDP-glucose 4-epimerase  - - 3.06 
Bbr_1586 lnpB Phosphotransferase family protein - - 3.36 
Bbr_1587 lnpA GH112 lacto-N-biose phorylase  - - 2.90 
Bbr_1588 gltC Permease protein of ABC transporter system for sugars  - - 2.91 
Bbr_1589 gltB Permease protein of ABC transporter system for sugars  - - 3.02 
Bbr_1590 gltA Solute-binding protein of ABC transporter system for sugars  - - 5.07 
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